A5041324986- Abdominal Trauma and Injuries
- Cardiovascular Syncope and Autonomic Disorders
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Antifungal resistance and susceptibility
- Pathogenesis and Treatment of Hiccups
- Infectious Diseases and Mycology
- Pharmacological Effects of Natural Compounds
- Medicinal Plant Pharmacodynamics Research
- Pelvic and Acetabular Injuries
- Ginseng Biological Effects and Applications
- Pregnancy-related medical research
- Peripheral Neuropathies and Disorders
First Hospital of Shanxi Medical University
2025
Shanxi Medical University
2025
Gansu University of Traditional Chinese Medicine
2025
Anhui Medical University
2024
Tra Vinh University
2023
Hebei General Hospital
2022
Ulcerative colitis (UC), a chronic and challenging condition, necessitates the development of more effective treatments owing to unsatisfactory efficacy side effects associated with current medications. Traditional Chinese medicine (TCM), known for its multi-stage multi-targeted approach, has long history in treating gastrointestinal diseases offering promising alternative UC treatment. Panax ginseng (P. ginseng), commonly used remedy TCM, exemplifies this potential, although specific...
Postural Orthostatic Tachycardia Syndrome (POTS) is a common condition affecting more than 170 people per 100,000 population. However, POTS following COVID-19 vaccination remains rare reporting in the medical literature.We, herein, summarize and highlight evidence that has been reported regarding POTS-like symptoms vaccination.We conducted literature search summarized findings form of narrative commentary. All types publications (case reports/series, original articles, letters to editors,...
The morbidity and mortality of chronic pulmonary aspergillosis (CPA) are very high. We aimed to investigate the prognostic factors patients with CPA, especially focusing on underlying disease probable co-infection bacterial.
Background: Ruxolitinib, a potent and selective inhibitor of Janus kinase 1 (JAK1)/JAK2 tyrosine kinases, was approved for treatment intermediate- high-risk patients with myelofibrosis (MF) based on the findings from pivotal studies, COMFORT I II. Although an Asia regional study conducted, enrolled Chinese population limited (N=63). Aims: We aimed to evaluate safety profile ruxolitinib in MF under routine clinical practice. Methods: This retrospective, non-interventional, multicenter,...